MX1013, a dipeptide caspase inhibitor with potent in vivo antiapoptotic activity

British Journal of Pharmacology

Volumn 140, Issue 2, 2003, Pages 402-412

  Yang, Wu ^a   Guastella, John ^a   Huang, Jin Cheng ^b   Wang, Yan ^a   Zhang, Li ^a   Xue, Dong ^b   Tran, Minhtam ^a   Woodward, Richard ^b   Kasibhatla, Shailaja ^a   Tseng, Ben ^a   Drewe, John ^a   Cai, Sui Xiong ^a  

^a Cytovia Inc   (United States)

^b Department of Pharmacokinetics and Drug Metabolism   (United States)

Author keywords

Apoptosis; Brain ischemia stroke; Caspase inhibitor; Cytoprotective; Liver failure; Myocardial infarction

Indexed keywords

BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; BLOOD CLOTTING FACTOR 10A; CALPAIN; CASPASE 3; CASPASE 6; CASPASE 7; CASPASE 8; CASPASE 9; CASPASE INHIBITOR; CATHEPSIN B; DNA FRAGMENT; FAS ANTIGEN; INTERLEUKIN 1BETA CONVERTING ENZYME; MX 1013; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; AQUEOUS SOLUTION; ARTICLE; BOLUS INJECTION; BRAIN ISCHEMIA; CELL CULTURE; CELL PROTECTION; CONTROLLED STUDY; DISEASE MODEL; DRUG INFUSION; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; HEART INJURY; HUMAN; HUMAN CELL; IC 50; LETHALITY; LIVER FAILURE; LIVER PROTECTION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT; REPERFUSION INJURY;

AMINO ACID CHLOROMETHYL KETONES; ANIMALS; APOPTOSIS; BRAIN ISCHEMIA; CASPASE 1; CASPASE 3; CASPASES; CYCLOHEXIMIDE; CYSTEINE PROTEINASE INHIBITORS; DIPEPTIDES; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; HELA CELLS; HUMANS; JURKAT CELLS; LIVER; MALE; MICE; MYOCARDIAL INFARCTION; POLY(ADP-RIBOSE) POLYMERASES; RATS; RATS, INBRED F344; TUMOR NECROSIS FACTOR-ALPHA;

EID: 10744233764     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705450     Document Type: Article

References (49)

1. ANVERSA, P., BEGHI, C., KIKKAWA, Y. & OLIVETTI, G. (1986). Myocardial infarction in rats. Infarct size, myocyte hypertrophy, and capillary growth. Circ. Res., 58, 26-37.
2. ARAVIND, L., DIXIT, V.M. & KOONIN, E.V. (1999). The domains of death: evolution of the apoptosis machinery. Trends Biochem. Sci., 24, 47-53.
3. BRAUN, J.S., NOVAK. R., HERZOG, K.H., BODNER, S.M., CLEVELAND, J.L. & TUOMANEN, E.I. (1999). Neuroprotection by a caspase inhibitor in acute bacterial meningitis. Nat. Med., 5, 298-302.
4. CURSIO, R., GUGENHEIM, J., RICCI, J.E., CRENESSE, D., ROSTAGNO, P., MAULON, L., SAINT-PAUL, M.C., FERRUA, B. & AUBERGER, A.P. (1999). A caspase inhibitor fully protects rats against lethal normothermic liver ischemia by inhibition of liver apoptosis. Faseb J., 13, 253-261.
5. DECKWERTH, T.L., ADAMS, L.M., WIESSNER, C., ALLEGRINI, P.R., RUDIN, M., SAUTER, A., HENGERER, B., SAYERS, R.O., ROVELLI, G., AJA, T., MAY, R., NALLEY, K., LINTON, S., KARANEWSKY, D.S., TERNANSKY, R.J., WU, J.C., ROGGO, S., SCHMITZ, A., CONTRERAS, P.C. & TOMASELLI, K.J. (2001). Long-term protection of brain tissue from cerebral ischemia by peripherally administered peptidomimetic caspase inhibitors. Drug Dev, Res., 52, 579-586.
6. ENDRES, M., NAMURA, S., SHIMIZU-SASAMATA, M., WAEBER, C., ZHANG, L., GOMEZ-ISLA, T., HYMAN, B.T. & MOSKOWITZ, M.A. (1998). Attenuation of delayed neuronal death after mild focal ischemia in mice by inhibition of the caspase family. J. Cereb. Blood Flow Metab., 18, 238-247.
7. FARBER, A., CONNORS, J.P., FRIEDLANDER, R.M., WAGNER, R.J., POWELL, R.J. & CRONENWETT, J.L. (1999). A specific inhibitor of apoptosis decreases tissue injury after intestinal ischemia-reperfusion in mice. J. Vasc. Surg., 30, 752-760.
8. GOTTLIEB, R.A. & ENGLER, R.L. (1999). Apoptosis in myocardial ischemia-reperfusion. Ann. N. Y. Acad. Sci., 874, 412-426.
9. GROBMYER, S.R., ARMSTRONG, R.C., NICHOLSON, S.C., GABAY, C., AREND, W.P., POTTER, S.H., MELCHIOR, M., FRITZ, L.C. & NATHAN, C.F. (1999). Peptidomimetic fluoromethylketone rescues mice from lethal endotoxic shock. Mol. Med., 5, 585-594.
10. HAN, B.H., XU, D., CHOI, J., HAN, Y., XANTHOUDAKIS, S.R., TAM, J., VAILLANCOURT, J., COLUCCI, J.. SIMAN, R., GIROUX, A., ROBERTSON, G.S., ZAMBONI, R., NICHOLSON, D.W. & HOLTZMAN, D.M. (2002). Selective, reversible caspase-3 inhibitor is neuroprotective and reveals distinct pathways of cell death after neonatal hypoxic-ischemic brain injury. J. Biol. Chem., 277, 30126-30136.
11. HARA, H., FRIEDLANDER, R.M., GAGLIARDINI, V., AYATA, C., FINK, K., HUANG, Z., SHIMIZU-SASAMATA, M., YUAN, J. & MOSKOWITZ, M.A. (1997). Inhibition of interleukin 1beta converting enzyme family proteases reduces ischemic and excitotoxic neuronal damage. Proc. Natl. Acad. Sci. U.S.A., 94, 2007-2012.
12. HAUNSTETTER, A. & IZUMO, S. (1998). Apoptosis: basic mechanisms and implications for cardiovascular disease. Circ. Res., 82, 1111-1129.
13. HOGLEN, N.C., HIRAKAWA, B.P., FISHER, C.D., WEEKS, S., SRINIVASAN, A., WONG, A.M., VALENTINO, K.L., TOMASELLI, K.J., BAI, X., KARANEWSKY, D.S. & CONTRERAS, P.C. (2001). Characterization of the caspase inhibitor IDN-1965 in a model of apoptosis-associated liver injury. J. Pharmacol. Exp. Ther., 297, 811-818.
14. HUANG, J.Q., RADINOVIC, S., REZAIEFAR, P. & BLACK, S.C. (2000). In vivo myocardial infarct size reduction by a caspase inhibitor administered after the onset of ischemia. Eur. J. Pharmacol., 402, 139-142.
15. JAESCHKE, H., FARHOOD, A., CAI, S.X., TSENG, B.Y. & BAJT, M.L. (2000). Protection against TNF-induced liver parenchymal cell apoptosis during endotoxemia by a novel caspase inhibitor in mice. Toxicol. Appl. Pharmacol., 169, 77-83.
16. KONDO, T., SUDA, T., FUKUYAMA, H., ADACHI, M. & NAGATA, S. (1997). Essential roles of the Fas ligand in the development of hepatitis. Nat. Med., 3, 409-413.
17. LAURA, R., ROBISON, D.J. & BING, D.H. (1980). (p-Amidinophenyl) methanesulfonyl fluoride, an irreversible inhibitor of serine proteases. Biochemistry, 19, 4859-4864.
18. LAZEBNIK, Y.A., KAUFMANN, S.H., DESNOYERS, S., POIRIER, G.G. & EARNSHAW, W.C. (1994). Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature, 371, 346-347.
19. LEE, D., LONG, S.A., ADAMS, J.L., CHAN, G., VAIDYA, K.S., FRANCIS, T.A., KIKLY, K., WINKLER, J.D., SUNG, C.M., DEBOUCK, C., RICHARDSON, S., LEVY, M.A., DEWOLF JR, W.E., KELLER, P.M., TOMASZEK, T., HEAD, M.S., RYAN, M.D., HALTIWANGER, R.C., LIANG, P.H., JANSON, C.A., MCDEVITT, P.J., JOHANSON, K., CONCHA, N.O., CHAN, W., ABDEL-MEGUID, S.S., BADGER, A.M., LARK, M.W., NADEAU, O.P., SUVA, L.J., GOWEN, M. & NUTTALL, M.E. (2000). Potent and selective nonpeptide inhibitors of caspases 3 and 7 inhibit apoptosis and maintain cell functionality. J. Biol. Chem., 275, 16007-16014.
20. LINTON, S.D., KARANEWSKY, D.S., TERNANSKY, R.J., WU, J.C., PHAM, B., KODANDAPANI, L., SMIDT, R., DIAZ, J.L., FRITZ, L.C. & TOMASELLI, K.J. (2002). Acyl dipeptides as reversible caspase inhibitors. Part 1: initial lead optimization. Bioorg. Med. Chem. Lett., 12, 2969-2971.
21. LODDICK, S.A., MACKENZIE, A. & ROTHWELL, N.J. (1996). An ICE inhibitor, z-VAD-DCB attenuates ischaemic brain damage in the rat. Neuroreport, 7, 1465-1468.
22. LOETSCHER, H., NIEDERHAUSER, O., KEMP, J. & GILL, R. (2001). Is caspase-3 inhibition a valid therapeutic strategy in cerebral ischemia? Drug Discov. Today, 6, 671-680.
23. MEYER, S.L., BOZYCZKO-COYNE, D., MALLYA, S.K., SPAIS, C.M., BIHOVSKY, R., KAYWOOYA, J.K., LANG, D.M., SCOTT, R.W. & SIMAN, R. (1996). Biologically active monomeric and heterodimeric recombinant human calpain I produced using the baculovirus expression system. Biochem. J., 314, 511-519.
24. MITTL, P.R., DI MARCO, S., KREBS, J.F., BAI, X., KARANEWSKY, D.S., PRIESTLE, J.P., TOMASELLI, K.J. & GRUTTER, M.G. (1997). Structure of recombinant human CPP32 in complex with the tetrapeptide acetyl-Asp-Val-Ala-Asp fluoromethyl ketone. J. Biol. Chem., 272, 6539-6547.
25. MOCANU, M.M., BAXTER, G.F. & YELLON, D.M. (2000). Caspase inhibition and limitation of myocardial infarct size: protection against lethal reperfusion injury. Br. J. Pharmacol., 130, 197-200.
26. MORITA, T., KATO, H., IWANAGA, S., TAKADA, K. & KIMURA, T. (1977). New fluorogenic substrates for alpha-thrombin, factor Xa, kallikreins, and urokinase. J. Biochem. (Tokyo), 82, 1495-1498.
27. MORRISON, J.F. & WALSH, C.T. (1988). The behavior and significance of slow-binding enzyme inhibitors. Adv. Enzymol. Relat. Areas Mol. Biol., 61, 201-301.
28. MURAKAMI, K., OHSAWA, T., HIROSE, S., TAKADA, K. & SAKA-KIBARA, S. (1981). New fluorogenic substrates for renin. Anal. Biochem., 110, 232-239.
29. NICHOLSON, D.W., ALI, A., THORNBERR, N.A., VAILLANCOURT, J.P., DING, C.K., GALLANT, M., GAREAU, Y., GRIFFIN, P.R., LABELLE, M., LAZEBNIK, Y.A., MUNDAY, N.A., RAJU, S.M., SMULSON. M.E., YAMIN, T.T., YU, V.L. & MILLER, D.R. (1995). Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature, 376, 37-43.
30. PRASAD, C.V.C., PROUTY, C.P., HOYER, D., ROSS, T.M., SALVINO, S.M., AWAD, M., GRAYBILL, T.L., SCHMIDT, S.J., OSIFO, I.K., DOLLE, R.E., HELASZEK, C.T., MILLER, R.E. & ATOR, M.A. (1995). Structural and stereochemical requirements of time-dependent inactivators of the interleukin-1 beta converting enzyme. Bioorg. Med. Chem. Lett., 5, 315-318.
31. REED, J.C. (2002). Apoptosis-based therapies. Nat. Rev. Drug Discov., 1, 111-121.
32. REVESZ, L., BRISWALTER, C., HENG, R., LEUTWILER, A., MUELLER, R. & WUETHRICH, H.J. (1994). Synthesis of P1 aspartate-based peptide acyloxymethyl and fluoromethyl ketones as inhibitors of interleukin-1 beta-converting enzyme. Tetrahedron Lett., 35, 9693-9696.
33. ROBERTSON, G.S., CROCKER, S.J., NICHOLSON, D.W. & SCHULZ, J.B. (2000). Neuroprotection by the inhibition of apoptosis. Brain Pathol., 10, 283-292.
34. RODRIGUEZ, I., MATSUURA, K., ODY, C., NAGATA, S. & VASSALLI, P. (1996). Systemic injection of a tripeptide inhibits the intracellular activation of CPP32-like proteases in vivo and fully protects mice against Fas-mediated fulminant liver destruction and death. J. Exp. Med., 184, 2067-2072.
35. ROTONDA, J., NICHOLSON, D.W., FAZIL, K.M., GALLANT, M., GAREAU, Y., LABELLE. M., PETERSON, E.P., RASPER, D.M., RUEL, R., VAILLANCOURT, J.P., THORNBERRY, N.A. & BECKER, J.W. (1996). The three-dimensional structure of apopain/CPP32, a key mediator of apoptosis. Nat. Struct. Biol., 3, 619-625.
36. SALVESEN, G.S. & DIXIT, V.M. (1999). Caspase activation: the induced-proximity model. Proc. Natl. Acad. Sci. U.S.A., 96, 10964-10967.
37. SCHULZ, J.B., WELLER, M. & MOSKOWITZ, M.A. (1999). Caspases as treatment targets in stroke and neurodegenerative diseases. Ann. Neural, 45, 421-429.
38. TALANIAN, R.V., BRADY, K.D. & CRYNS, V.L. (2000). Caspases as targets for anti-inflammatory and anti-apoptotic drug discovery. J. Med. Chem., 43, 3351-3371.
39. TCHOUPE, J.R., MOREAU, T., GAUTHIER, F. & BIETH, J.G. (1991). Photometric or fluorometric assay of cathepsin B, L and H and papain using substrates with an aminotrifluoromethylcoumarin leaving group. Biochem. Biophys. Acta, 1076, 149-151.
40. THOMPSON, C.B. (1995). Apoptosis in the pathogenesis and treatment of disease. Science, 267, 1456-1462.
41. THORNBERRY, N.A. (1994). Interleukin-1 beta converting enzyme. Methods Enzymol, 244, 615-631.
42. THORNBERRY, N.A. (1998). Caspases: key mediators of apoptosis. Chem. Biol, 5, R97-R103.
43. THORNBERRY, N.A. & LAZEBNIK, Y. (1998). Caspases: enemies within. Science, 281, 1312-1316.
44. THORNBERRY, N.A., PETERSON, E.P., ZHAO, J.J., HOWARD, A.D., GRIFFIN, P.R. & CHAPMAN, K.T. (1994). Inactivation of interleukin-1 beta converting enzyme by peptide (acyloxy)methyl ketones. Biochemistry, 33, 3934-3940.
45. THORNBERRY, N.A., RANO, I.A., PETERSON, E.P., RASPER, D.M., TIMKEY, T., GARCIA-CALVO, M., HOUTZAGER, V.M., NORDSTROM, P.A., ROY, S., VAILLANCOURT, J.P., CHAPMAN, K.T. & NICHOLSON, D.W. (1997). A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis. J. Biol. Chem., 272, 17907-17911.
46. WEI, Y., FOX, T., CHAMBERS, S.P., SINTCHAK, J., COLL, J.T., GOLEC, J.M., SWENSON, L., WILSON, K.P. & CHARIFSON, P.S. (2000). The structures of caspases-1, -3, -7 and -8 reveal the basis for substrate and inhibitor selectivity. Chem. Biol, 1, 423-432.
47. WELLINGTON, C.L. & HAYDEN, M.R. (2000). Caspases and neuro-degeneration: on the cutting edge of new therapeutic approaches. Clin. Genet., 57, 1-10.
48. YAOITA, H., OGAWA, K., MAEHARA, K. & MARUYAMA, Y. (1998). Attenuation of ischemia/reperfusion injury in rats by a caspase inhibitor. Circulation, 97, 276-281.
49. ZIMMERMANN, K.C. & GREEN, D.R. (2001). How cells die: apoptosis pathways. J. Allergy Clin. Immunol., 108, S99-S103.